A Multiple Target Approach To Universal Influenza Vaccine Development

Source: Cytiva

With a unique multi-target approach, what it considers the world's best adjuvant, and a host of learnings from the successes and failures of COVID-19 vaccine efforts, Longhorn Vaccines & Diagnostics is gaining steam in its pursuit of a universal influenza vaccine. On this episode of the Business of Biotech, Longhorn Vaccines Co-Founder and President Jeff Fischer gives us a transparent look at the science and the partnerships that are giving him cause to believe his company will succeed where so many have failed.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online